Today: 23 November 2025
Subscribe
Browse Category

Investment News News 16 October 2025 - 20 October 2025

Nuclear SPAC Stock Skyrockets: Terrestrial Energy’s SPAC Deal Ignites Investor Frenzy

Nuclear SPAC Stock Skyrockets: Terrestrial Energy’s SPAC Deal Ignites Investor Frenzy

Terrestrial Energy is a Generation-IV nuclear developer known for its IMSR technology ts2.tech businesswire.com. The IMSR is a modular molten-salt reactor that uses low-enriched uranium; it is inherently safe thanks to its fuel salt and temperature control design ts2.tech globenewswire.com. Terrestrial has been building regulatory momentum: besides the recent NRC ruling, Canada’s regulator completed a positive Vendor Design Review in 2023, finding no fundamental barriers to licensing” the IMSR for commercial use globenewswire.com. The company plans to build first IMSR plants in the early 2030s and markets them not only for electricity but also high-temperature industrial heat (data centers, chemical
20 October 2025
 ·  ·  ·  ·  · 
Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (NASDAQ: SLS) stock has surged roughly 100% year-to-date, closing around $2.14 on Oct. 17, 2025 ts2.tech ts2.tech (versus a 52-week low of $0.77). In after-hours trading on Oct. 17 it spiked another +38%, briefly touching a new 52-week high ts2.tech. Big investors are piling in: BlackRock disclosed a 5.4% stake (~5.7M shares) in SLS on Oct. 18 ts2.tech, and other funds like Vanguard and Marshall Wace added millions of shares in Q2 quiverquant.com. On the drug-development front, Sellas’s lead AML immunotherapy (galinpepimut‑S, GPS”) is in a Phase 3 AML trial (REGAL), which recently passed an interim safety review
20 October 2025
 ·  ·  ·  ·  · 
Summit Therapeutics (SMMT) Skyrockets on Cancer Breakthrough – Key Facts & Outlook

Summit Therapeutics (SMMT) Skyrockets on Cancer Breakthrough – Key Facts & Outlook

SMMT Stock’s Wild Ride in 2025 Summit Therapeutics’ share price has been on a roller-coaster ride this year. After a steady climb through late summer, SMMT spiked above $25 intraday in mid-October, then pulled back to end last week just under $21 ts2.tech. The stock fell 4.5% on Friday, Oct. 17 alone ts2.tech as traders braced for the upcoming data presentation and earnings call. Even after that dip, Summit shares remain up solidly in 2025 (low double-digit percent gains) – roughly in line with the broader biotech sector (the SPDR S&P Biotech ETF is ~+20% YTD) ts2.tech. These dramatic swings
20 October 2025
 ·  ·  ·  ·  · 
Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

RANI Stock Price Skyrockets on Deal News Rani’s stock price skyrocketed after the company unveiled its landmark partnership and financing news. On Friday, Oct. 17, 2025, RANI opened around $1.37 and surged as high as $2.39 intraday before settling at a $1.64 closing price – a stunning +248% one-day gain investing.com. The prior day, RANI had closed at just $0.47, so the news sparked an almost threefold leap in value. In pre-market trading before the open, the stock had already jumped over +150%, and it continued to rally after the bell ts2.tech ts2.tech. By midday Oct. 17, shares were still
20 October 2025
 ·  ·  ·  ·  · 
Broadcom’s AI Windfall: Inside AVGO’s Trillion-Dollar Surge, $10B Chip Deal & 2025 Outlook

Broadcom (NASDAQ: AVGO): What to Know Before Markets Open on October 20, 2025

Broadcom’s AI Jackpot: Stock Soars on OpenAI Deal as Analysts Bet Big on AVGO Broadcom Stock on a Tear, Fueled by AI Hype Broadcom’s stock has been on a remarkable tear in 2023–2025, reaching trillion-dollar territory as it rides the wave of AI optimism. After a 10-for-1 stock split in February 2024 (which made shares more affordable to retail investors), Broadcom’s market capitalization skyrocketed, surpassing $1.5 trillion by late 2025 ts2.tech. The stock hit an all-time high around $374 in early September. Even after a mild pullback, AVGO remains up roughly 70% year-to-date, vastly outperforming the S&P 500’s ~15% gain ts2.tech ts2.tech.
19 October 2025
 ·  ·  ·  ·  · 
Battle of the EV Charging Standards: Tesla’s NACS vs. CCS2 vs. CHAdeMO – Who Will Rule the Roads in 2025?

Tesla Stock’s Wild Ride: TSLA Soars on Record Sales, Sinks on ‘Budget’ EV News – What’s Next?

Tesla Stock on Oct 18: Recent Performance As of this weekend (Oct. 18, 2025), Tesla’s stock is hovering in the high-$420s per share, just shy of the peaks it hit earlier in the month ts2.tech. On Oct. 6, TSLA reached roughly $453, a 52-week high, before pulling back amid profit-taking ts2.tech. The past week saw notable volatility: shares jumped about 5% on Oct. 13 to ~$436, then slid ~1.5% on Oct. 14 to the $429 range ts2.tech. By Friday’s close, the stock was relatively flat in the mid-$420s. Despite these swings, Tesla has dramatically outperformed the broader market in 2025
18 October 2025
 ·  ·  ·  ·  · 
GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL’s logo at company headquarters. The Menlo Park biotech specializes in blood-based early cancer screening through its Galleri test news.samsung.com tradingview.com. GRAIL, Inc. is focused on early cancer detection – its mission is to detect cancer early when it can be cured” news.samsung.com. The company’s Galleri test analyzes tumor DNA in blood to screen for dozens of cancers in asymptomatic adults. Recently, two developments have driven the stock: Samsung’s strategic deal (announced Oct. 16) and positive trial data (released at ESMO). These moves suggest GRAIL is gaining traction, but they also highlight the challenges ahead in turning cutting-edge science into
18 October 2025
 ·  ·  ·  ·  · 
GE Aerospace Stock Rockets as Rally Continues – Q3 Earnings, Contracts, and Analyst Targets in Focus

GE Aerospace Stock Rockets as Rally Continues – Q3 Earnings, Contracts, and Analyst Targets in Focus

Surging Stock Performance GE Aerospace (NYSE: GE) shares have been on a tear in 2025, roughly doubling from lows. As of Oct 17, 2025, the stock closed around $300 reuters.com. That’s up about 78% this year intelligentinvestor.com.au – one of the best performances among mega-cap industrials. The 52-week high is $307.25 and the low was $159.36 reuters.com, reflecting a remarkable rebound as the company emerged as a pure-play aerospace engine maker. (Before April 2024, GE had spun off its energy and healthcare units, leaving GE Aerospace” as its primary business under ticker GE.) Trading volumes have been healthy (typically >1M
18 October 2025
 ·  ·  ·  ·  · 
BigBear.ai (BBAI) Stock Rockets 80% in 2025 – Is the Defense-AI Rally Just Beginning?

BigBear.ai’s Stock Skyrockets on Defense AI Deals – Is BBAI the Next Palantir? 🚀

Stock Price Soars Amid Defense AI Boom BigBear.ai’s stock has been on a tear in October as investors pile into defense-focused AI names. On October 13, shares spiked 22% in a single day after the company announced a new AI partnership, leaping from the mid-$7 range to about $8.80 ts2.tech. It was BBAI’s biggest one-day jump in over a year. Heavy trading continued as the rally carried into Oct. 14, when the stock hit an intraday high of $9.39 stockinvest.us. By mid-week, BBAI hovered near $9 – more than double its value at the start of 2025 ts2.tech. However, the
18 October 2025
 ·  ·  ·  ·  · 
Interactive Brokers Stock Soars After Q3 Earnings Beat, 40% Asset Surge

Interactive Brokers Stock Soars After Q3 Earnings Beat, 40% Asset Surge

Interactive Brokers Group (NASDAQ: IBKR) is making headlines after delivering standout third-quarter results on October 16, 2025, which sent its stock into focus. The online brokerage reported earnings and revenue that topped analyst expectations, fueling optimism among investors. IBKR’s shares closed at $68.52 after the earnings release – marking an impressive rise of about 83% over the past 12 months investing.com (and roughly 56% year-to-date, buoyed by a 4-for-1 stock split in June 2025 ts2.tech). Below we break down the key facts and expert insights on what’s driving Interactive Brokers’ stock and what may be next. Key Facts Stock Price
17 October 2025
 ·  ·  ·  ·  · 
Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones

Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones

Femasys’ stock surge on Oct. 16 mirrors growing investor interest in its reproductive healthcare pipeline. The company’s FemaSeed™ technology is designed to boost pregnancy rates by delivering sperm directly into the fallopian tube, and published trials report more than double the pregnancy rate of traditional intrauterine insemination globenewswire.com stocktitan.net. Femasys is positioning FemaSeed as a first-line, lower-cost infertility option ahead of IVF. Meanwhile, FemBloc offers a first-of-its-kind permanent birth control that creates a natural scar in the fallopian tubes, avoiding surgery ir.femasys.com ir.femasys.com. This week’s ASRM announcement – coinciding with broader fertility news – helped lift FEMY. Also on Oct. 16, national media reported an expected
16 October 2025
 ·  ·  ·  ·  · 
Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

Recent Market Moves Kenvue’s stock (NYSE: KVUE) has been volatile. On Oct 16, 2025 it closed around $15.46, marking a fresh 52-week low investing.com. Over the prior week the shares had slid ~13%, partly driven by jitters over UK talc lawsuits and Trump-era Tylenol claims. Investors bid on options, with call volume surging 52% on Oct 13 marketbeat.com, even as the stock dipped 2.9% that day to $16.17 marketbeat.com. Year-to-date KVUE is roughly flat to down modestly, but it lags the broader market. For context, the S&P 500 was nearly unchanged while Kenvue was down ~5% on Oct 16. A
16 October 2025
 ·  ·  ·  ·  · 
1 … 17 18 19 20 21 … 25
Go toTop